


Cardio Diagnostics, Aimil and Dr. Lal PathLabs partner to launch PrecisionCHD™ test in India

08 January 2026 | News

Helps in better identification and management of coronary heart disease in India



Cardio Diagnostics Holdings, Aimil Ltd. and Dr. Lal PathLabs have announced a strategic agreement to launch Cardio Diagnostics' PrecisionCHD™ Test for the identification and management of coronary heart disease (CHD) in India.

This partnership marks Cardio Diagnostics' first expansion outside the United States and an official entry into the Indian market. It is also a major step towards making the advanced technology of Cardio Diagnostics available in India, where cardiovascular disease remains a major and growing health problem. The prevalence rate of coronary heart disease (CHD) in India varies depending on the population, with prevalence rates of up to 7.4% and 13% recorded in rural and urban areas, respectively.

PrecisionCHD is a clinical blood test that can combine the science of epigenetics and genetics with AI technology to identify coronary heart disease (CHD) at the molecular level. This clinically accredited test helps physicians understand the main molecular cause of the disease, which is very important for personalized treatment and continued management. In addition to the prevented CHDs that can be detected with an angiogram, the PrecisionCHD test can also detect CHDs that are not normally detected by an angiogram. The data supporting the potential of PrecisionCHD include information on the detection of ischemia with no obstructive coronary arteries (INOCA) and myocardial infarction with no obstructive coronary arteries (MINOCA), two common types of nonobstructive disease. Recently it was presented at the scientific meeting of the American Heart Association held in New Orleans, Louisiana.

The initial phase of this partnership has already begun. The focus is on scaling up and scaling up the test to Dr. Lal PathLabs' larger lab and clinical network so that it is in accordance with India's clinical and regulatory regulations. Once this process is complete, work will be done on a commercial scale on a large scale, which is expected in 2026.